To the Editor
=============

Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder and anemia with transfusion dependency is detected in up to 60% of patients \[[@B1]\]. Early recognition of patients at risk of heart failure is difficult because global ventricular function and exercise capacity in chronically transfused patients may remain normal until late in the disease \[[@B2]\].

We evaluated three groups of MDS patients: cases with transfusion dependency (T-MDS), patients without transfusion dependency (NT-MDS) and age-matched controls. Transfusion dependency was considered as reported by Malcovati et al. \[[@B3]\]. Echo-Doppler, tissue velocity imaging and strain measures were obtained using General Electric-Healthcare (GE, Vivid-7) system with a matrix probe M3S.

Parametric data were analyzed by "one-way" analyzes of variance (ANOVA) with Bonferroni's Multiple Comparison as a post-test. Non-parametric data were analyzed by Kruskal-Wallis. The studies of correlation was assessed by Pearson's correlation coefficient (r).

The three groups were composed of 13 T-MDS, 21 NT-MDS and 14 controls. There were no significant differences between groups. See Table [1](#T1){ref-type="table"}. Table [2](#T2){ref-type="table"} presents the echocardiographic parameters. The average values of ventricular end-systolic and end-diastolic volumes in T-MDS group were significantly higher than NT-MDS and controls (p \<0.05 and p \<0.04 respectively). The left atrial volume indexed (LAV index) was significantly larger in patients of T-MDS group than NT-MDS and controls (35.9 ± 15 mL/m^2^, 26.6 ± 5,2 mL/m^2^, 22.8 ± 8 mL/m^2^ respectively) (p \<0.004.). A strong correlation between hemoglobin levels and LVEDV (left ventricular end-diastolic volume*)*, LVESV (left ventricular end-systolic volume*)*, LAV (left atrial volume) and LAV index was observed, with **r** values of −0.4, -0.4, -0.53 and 0.51 respectively (p \<0.02, p \<0.02, p \<0.002 and p \<0.002 respectively). See Figure [1](#F1){ref-type="fig"}**.** Otherwise, we found no correlation between ferritin levels and echocardiographic parameters.

###### 

Patients were diagnosed and classified according to WHO, IPSS and WPSS criteria

  **Patient**   **WHO**   **IPSS**   **Serum Ferritin**   **Transfusion therapy**   **Transfusional dependent**   **WPSS**
  ------------- --------- ---------- -------------------- ------------------------- ----------------------------- -----------
  **1**         RA        NA         288,8                No transfusion therapy    NO                            NA
  **2**         RAEB 2    INT 1      94,7                 No transfusion therapy    NO                            HIGH
  **3**         RCMD      INT 1      416,5                14 RCC                    NO                            LOW
  **4**         RARS      INT 1      1.994,0              69 RCC                    Yes                           LOW
  **5**         RA        NA         826,0                No transfusion therapy    NO                            NA
  **6**         RA        LOW        22,4                 No transfusion therapy    NO                            LOW
  **7**         MDS-T     NA         3.484,0              42 RCC                    Yes                           NA
  **8**         RARS      NA         1.399,0              64 RCC                    Yes                           NA
  **9**         RCMD      NA         7.107,0              81 RCC                    Yes                           NA
  **10**        RARS      LOW        1.587,0              20 RCC                    Yes                           LOW
  **11**        RARS      INT 1      132,0                04 RCC                    NO                            INT
  **12**        RARS      LOW        1.937,8              82 RCC                    Yes                           LOW
  **13**        RARS      NA         541,0                No transfusion therapy    NO                            NA
  **14**        RA        LOW        307,0                No transfusion therapy    NO                            VERY LOW
  **15**        RCMD      INT 1      5.113,1              96 RCC                    Yes                           INT
  **16**        RCMD      LOW        38,0                 No transfusion therapy    NO                            LOW
  **17**        RCMD      NA         98,0                 03 RCC                    NO                            NA
  **18**        RARS      LOW        318,0                No transfusion therapy    NO                            VERY LOW
  **19**        RCMD      LOW        87,0                 No transfusion therapy    NO                            LOW
  **20**        RCMD      NA         765,0                38 RCC                    Yes                           NA
  **21**        RCMD      INT 1      780,0                17 RCC                    Yes                           HIGH
  **22**        RARS      LOW        356,2                No transfusion therapy    NO                            VERY LOW
  **23**        RCMD      INT 1      298,4                No transfusion therapy    NO                            LOW
  **24**        RCMD      INT 1      2.160,0              24 RCC                    Yes                           HIGH
  **25**        RA        LOW        86,4                 No transfusion therapy    NO                            VERY LOW
  **26**        RCMD      NA         276,0                No transfusion therapy    NO                            NA
  **27**        RCMD      NA         1.922,3              24 RCC                    Yes                           NA
  **28**        RAEB 2    INT 2      1.022,0              42 RCC                    Yes                           VERY HIGH
  **29**        RARS      NA         321,0                No transfusion therapy    NO                            NA
  **30**        RCMD      NA         223,0                12 RCC                    Yes                           NA
  **31**        RAEB 1    INT 1      229,0                03 RCC                    NO                            VERY LOW
  **32**        RCMD      INT 1      132,4                No transfusion therapy    NO                            INT
  **33**        RCMD      NA         556,0                04 RCC                    NO                            NA
  **34**        RCMD      NA         850,0                10 RCC                    NO                            NA

Legend. MDS unclassifiable; RA, refractory anemia; RAEB, RA with excess of blasts; RARS, RA with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; t-MDS, therapy-related MDS; WHO, World Health Organization. red cell concentrate -- RCC. NA -Not applicable, due to cytogenetics by G-banding without metaphases).

###### 

Echocardiographic parameters of patients and controls

                                                                                                     ***Controls(14)***           ***NT-MDS(21)***             ***T-MDS(13)***               ***P value***
  -------------------------------------------------------------------------------------------------- ---------------------------- ---------------------------- ----------------------------- ---------------
  **Baseline demographics and characteristics**                                                                                                                                              
  *Age (year)*                                                                                       72.4 ± 8 (58--84)            70.3 ± 14 (47--88)           65.2 ± 20 (27--90)            NS
  *Gender (m/f)*                                                                                     (6/8)                        (7/14)                       (6/7)                          
  *Body weigth (kg)*                                                                                 66.0 ± 11.9 (46 -- 83)       63.7 ± 10.1 (43.6 -- 91.3)   64.9 ± 10.1 (49.3 -- 90)      NS
  *Height (m)*                                                                                       1.59 ± 0.09 (1.45 -- 1.75)   1.57 ± 0.07 (1.46 -- 1.72)   1.59 ± 0.08 (1.45 -- 1.70)    NS
  *BSA (m*^*2*^*)*                                                                                   1.68 ± 0.16 (1.42 -- 1.98)   1.64 ± 0.15 (1.33 -- 2.01)   1.67 ± 0.15 (1.4 -- 2.01)     NS
  *BMI (kg/m*^*2*^*)*                                                                                26.2 ± 5.7 (19.1 -- 36.9)    25.8 ± 2.9 (20.5 -- 32.3)    25.5 ± 3.7 (21.4 -- 32.7)     NS
  *HR (bpm)*                                                                                         75.8 ± 5.4 (66--83)          77.6 ± 1.4 (66--88)          78.4 ± 2.2(65--90)            NS
  *SBP (mmHg)*                                                                                                                    139.2 ± 19 (110--180)        121.8 ± 16 (100--150)         \<0.02
  *DBP (mmHg)*                                                                                                                    77.9 ± 12 (60--108)          70 ± 9.6 (60--90)             NS
  *Hb (g/dL)*                                                                                                                     9.85 ± 1.8 (6.6 - 12.7)      6.5 ± 1.7 (3.8 - 9.9)         \<0.001
  *Ferritin (ng/mL)*                                                                                                              298.8 ± 234 (22.4 a 850)     2269 ± 1931 (223 a 7101)      \<0.001
  ***Chamber quantification and ejection fraction of patients and controls***                                                                                                                
  *LVDD (mm)*                                                                                        *46.0 ± 4.7 (40--57)*        *48.5 ± 3.9 (41--56)*        *49.3 ± 6.6 (40--64)*         *NS*
  *LVSD (mm)*                                                                                        *26.9 ± 4.9 (19--39)*        *27.7 ± 3.7 (22--37)*        *29.5 ± 6.8 (23--50)*         *NS*
  *IVS (mm)*                                                                                         *8.9 ± 2.3 (6--16)*          *8.5 ± 0.9 (7--11)*          *8.9 ± 1.4 (7--12)*           *NS*
  *LVPW (mm)*                                                                                        *8.5 ± 1.7 (6--13)*          *8.4 ± 0.7 (7--10)*          *8.8 ± 1.4 (7--12)*           *NS*
  *MASS (g)*                                                                                         *165.9 ± 61,0 (79--326)*     *173.8 ± 34.1 (116--249)*    *165.9 ± 61.0 (90--321)*      *NS*
  *MASS index (g/m*^*2*^*)*                                                                          *101.3 ± 37 (55.6 - 185)*    *106 ± 18 (73--140.7)*       *110 ± 37.1 (56.2 - 198)*     *NS*
  *EF%TEI*                                                                                           *71.8 ± 7.6 (58.2 - 89)*     *71.9 ± 6.5 (58.8 - 80.1)*   *69.8 ± 9.3 (43.6 - 83.9)*    *NS*
  *FS (%)*                                                                                           *41.4 ± 6.8 (31.2 - 58)*     *41.6 ± 5.7 (31--48.7)*      *39.4 ± 7.2 (22--53)*         *NS*
  *LA (mm)*                                                                                          *32 ± 4.2 (27--44)*          *33.4 ± 4.2 (28--43)*        *36.5 ± 4.9 (31--46)*         *\<0.04\**
  *EF%SIM*                                                                                           *67.7 ± 7.3 (50.1 - 81.3)*   *66.2 ± 4.8 (55.2 - 76.1)*   *64.7 ± 5.4 (50.7 - 70.8)*    *NS*
  *LVEDV (ml)*                                                                                       *65.5 ± 18 (37--105)*        *85.1 ± 29.9 (44--169)*      *92.8 ± 36.1 (49--189)*       *\<0.05\**
  *LVESV (ml)*                                                                                       *20.5 ± 6.2 (10--28)*        *28.7 ± 11.9 (12.5 - 65)*    *33.8 ± 19.7 (15--93)*        *\<0.04\**
  *LAV (ml)*                                                                                         *39.1 ± 14.5 (17--69)*       *43.5 ± 10.3 (25--64)*       *59.8 ± 24.8 (29--120)*       *\<0.006\*\**
  *LAV index (mL/m*^*2*^*)*                                                                          *22.8 ± 8 (10.5 - 39.6)*     *26.5 ± 5.2 (15.9 - 34.8)*   *35.9 ± 15 (18.8 - 70.9)*     *\<0.004\*\**
  ***Doppler parameters (transmitral and myocardial tissue) and strain of patients and controls***                                                                                           
  *Evel(cm/s)*                                                                                       77.2 ± 13.2 (55.4 - 105)     89.6 ± 20 (63--128)          96.6 ± 14.2 (68.5 - 116)      \<0.02\*
  *Avel(cm/s)*                                                                                       94.3 ± 18 (68.6 - 137.3)     100.2 ± 19 (68.5 - 131)      100.6 ± 27 (52.8 - 145)       NS
  *E/A*                                                                                              0.83 ± 0.2 (0.6 - 1.2)       0.9 ± 0.2 (0.6 - 1.4)        1.0 ± 0.26 (0.64 - 1,6)       NS
  *Em(cm/s)*                                                                                         8.6 ± 3.2 (4.1 - 14)         9.3 ± 2.4 (5.4 - 14)         10.4 ± 2.5 (7.5 a 14.8)       NS
  *E/Em*                                                                                             10 ± 3.4 (5.3 - 16.2)        10.3 ± 3,9 (5.6 - 20)        9.7 ± 2.9 (5.9 - 14.4)        NS
  *LV-Sm(cm/s)*                                                                                      6.5 ± 1.3 (5.1 - 9.5)        7.9 ± 1.3 (5.5 - 10.8)       7.8 ± 1.3 (6--10,3)           \<0.02\*
  *RV-Sm(cm/s)*                                                                                      10.1 ± 0.7 (9.1 - 11)        11.4 ± 3.3 (7.6 - 19)        12.3 ± 1,5 (9.8 - 14,7)       NS
  *TAPSE(mm)*                                                                                        24.9 ± 4.2 (20--33)          28.2 ± 5.3 (21--39)          28.9 ± 5 (22--40)             NS
  *VD basal(mm)*                                                                                     30.1 ± 6.4 (22--48)          31.7 ± 4 (24--41)            31.5 ± 4 (23--39)             NS
  *ST2DL (%)*                                                                                        −19.9 ± 2.7 (−24 to −13)     −20.7 ± 2.5 (−25 to −16,8)   −20.9 ± 1.4 (−23 to - 18,6)   NS

Legend. NT-MDS: non-transfused patients; T-MDS: transfused patients; LVDD: left ventricular diastolic diameter; LVSD: left ventricular systolic diameter; IVS: inter-ventricular septum; LVPW: left ventricular posterior wall; MASS: left ventricular mass; EF%TEI: ejection fraction Teicholz; FS: fractional shortening; LA: left atrial diameter; EF%SIM: ejection fraction Simpson; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; LAV: left atrial volume.

![**Linear correlation between left cardiac volumes and values of hemoglobin. A.***LAV: left atrial volume.***B.***LVEDV: left ventricular end-diastolic volume;***C.***LAV index : left atrial volume index.***D.***LVESV: left ventricular end-systolic volume.*](1756-8722-5-30-1){#F1}

The reduction of blood viscosity in severe anemia increases blood return \[[@B4]\] and ventricular preload which lead to atrial and ventricular enlargement observed in T-MDS patients. Confirming this hypothesis, these results are correlated to hemoglobin levels.

The T-MDS group showed no clinical sign of cardiac dysfunction. Otherwise, cardiac alterations were detected by tissue-doppler echocardiography, a relative fast and cheap bedside method to evaluate heart function. Echocardiography should be routinely performed in MDS patients to detect preclinical cardiac alterations and prevent more heart insults in these group of chronic anemic aged patients.

Abbreviation
============

NT-MDS, Non-transfused patients; T-MDS, Transfused patients; LVDD, Left ventricular diastolic diameter; LVSD, Left ventricular systolic diameter; IVS, Inter-ventricular septum; LVPW, Left ventricular posterior wall; LVEDV, Left ventricular end-diastolic volume; LVESV, Left ventricular end-systolic volume; LAV, Left atrial volume; RCC, Red cell concentrate; VD, Ventricular dysfunction.
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